---
schema_version: "secwatch.filing_event.v1"
accession: "0001157523-23-001659"
form_type: "8-K"
ticker: "AGEN"
cik: "0001098972"
company_name: "AGENUS INC"
filed_at: "2023-11-07T23:59:59+00:00"
generated_at: "2026-06-08T13:24:21.648180+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Agenus Q3 net loss $64.5M; cash falls to $106.3M; BLA for botensilimab planned mid-2024

## Summary
- Net loss of $64.5M for Q3 2023, compared to $56.7M in Q3 2022; nine-month loss $208.9M.
- Cash, equivalents, and short-term investments $106.3M at Sep 30, down 45% from $193.4M at Dec 31, 2022.
- Total revenue Q3 $24.3M, up 7% YoY; driven by non-cash royalty revenue of $20.4M.
- BLA submission for botensilimab/BAL in MSS CRC planned mid-2024; milestone payment from BMS partnership expected by end of 2023.
- Pursuing non-dilutive financing: selling non-strategic assets and partial milestone/royalty sales, expected to close by H1 2024.

## SEC filing metadata
- accession: 0001157523-23-001659
- form_type: 8-K
- ticker: AGEN
- cik: 0001098972
- company_name: AGENUS INC
- filed_at: 2023-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1098972/000115752323001659/0001157523-23-001659-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1098972/000115752323001659/a53764435.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001157523-23-001659
- JSON: https://secwatch.observer/filing/0001157523-23-001659.json
- Plain text: https://secwatch.observer/filing/0001157523-23-001659.txt

## Key facts
- Earnings Releases
  AGENUS INC reported financial results for the third quarter 2023.
  - Period: the third quarter 2023
  - Result: reported results
  source text: On November 7, 2023, Agenus Inc. announced its financial results for the quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1098972/000115752323001659/0001157523-23-001659-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.